Results 181 to 190 of about 887,968 (372)
Fatal Bronchial Asthma: A Series of Fifteen Cases with a Review of the Literature [PDF]
Beryl Earle
openalex +1 more source
What does it mean? Translating anatomical language to engage public audiences
Abstract The language of anatomy, with its roots in Ancient Greek and Roman languages, is complex and unfamiliar to many. Its complexity creates a significant barrier to public knowledge and understanding of anatomy—many members of the public find themselves asking “what does it mean?”, and this can manifest as poor health literacy and outcomes.
Kat A. Sanders, Adam M. Taylor
wiley +1 more source
Aims To assess adherence to guideline recommendations among a large network of Italian cardiology sites in the management of acute and chronic heart failure (HF) and to evaluate if an ad‐hoc educational intervention can improve their performance on several pharmacological and non‐pharmacological indicators.
Michele Massimo Gulizia+197 more
wiley +1 more source
A pseudo-outcome-based framework to analyze treatment heterogeneity in survival data using electronic health records [PDF]
An important aspect of precision medicine focuses on characterizing diverse responses to treatment due to unique patient characteristics, also known as heterogeneous treatment effects (HTE), and identifying beneficial subgroups with enhanced treatment effects. Estimating HTE with right-censored data in observational studies remains challenging. In this
arxiv
Die nasalen Reflexneurosen, insbesondere das nasale Asthma und die experimentelle Trigeminusforschung1) [PDF]
Helen F. Krause
openalex +1 more source
Abstract Aim Dipeptidyl peptidase‐1 (DPP‐1) inhibitors have been studied for the treatment of neutrophil‐mediated inflammatory diseases including bronchiectasis, bronchial asthma and cystic fibrosis. This study evaluated the pharmacokinetics, pharmacodynamics, safety and tolerability of DPP‐1 inhibitor HSK31858 in healthy Chinese volunteers.
Yuhao Wang+7 more
wiley +1 more source
A CRITICAL STUDY OF SIXTY-ONE CASES OF ASTHMA AND ECZEMA IN INFANCY AND CHILDHOOD CONTROLLED BY CUTANEOUS PROTEIN SENSITIZATION TESTS [PDF]
Harold Herman
openalex +1 more source
Abstract Aim TAS5315 is a Bruton tyrosine kinase (Btk) inhibitor in development for autoimmune and allergic diseases, including rheumatoid arthritis (RA) and chronic spontaneous urticaria (CSU). Two clinical studies evaluated the pharmacology and safety of single and multiple oral doses of TAS5315.
Yuji Kumagai+4 more
wiley +1 more source